Lock, Stock and Barrel : Role of Renin-Angiotensin-Aldosterone System in Coronavirus Disease 2019

Since the end of 2019, the medical-scientific community has been facing a terrible pandemic caused by a new airborne viral agent known as SARS-CoV2. Already in the early stages of the pandemic, following the discovery that the virus uses the ACE2 cell receptor as a molecular target to infect the cells of our body, it was hypothesized that the renin-angiotensin-aldosterone system was involved in the pathogenesis of the disease. Since then, numerous studies have been published on the subject, but the exact role of the renin-angiotensin-aldosterone system in the pathogenesis of COVID-19 is still a matter of debate. RAAS represents an important protagonist in the pathogenesis of COVID-19, providing the virus with the receptor of entry into host cells and determining its organotropism. Furthermore, following infection, the virus is able to cause an increase in plasma ACE2 activity, compromising the normal function of the RAAS. This dysfunction could contribute to the establishment of the thrombo-inflammatory state characteristic of severe forms of COVID-19. Drugs targeting RAAS represent promising therapeutic options for COVID-19 sufferers.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:10

Enthalten in:

Cells - 10(2021), 7 vom: 11. Juli

Sprache:

Englisch

Beteiligte Personen:

Zanza, Christian [VerfasserIn]
Tassi, Michele Fidel [VerfasserIn]
Romenskaya, Tatsiana [VerfasserIn]
Piccolella, Fabio [VerfasserIn]
Abenavoli, Ludovico [VerfasserIn]
Franceschi, Francesco [VerfasserIn]
Piccioni, Andrea [VerfasserIn]
Ojetti, Veronica [VerfasserIn]
Saviano, Angela [VerfasserIn]
Canonico, Barbara [VerfasserIn]
Montanari, Mariele [VerfasserIn]
Zamai, Loris [VerfasserIn]
Artico, Marco [VerfasserIn]
Robba, Chiara [VerfasserIn]
Racca, Fabrizio [VerfasserIn]
Longhitano, Yaroslava [VerfasserIn]

Links:

Volltext

Themen:

ACE inhibitors
ACE2
ACE2 protein, human
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme 2
COVID-19
EC 3.4.17.23
Journal Article
Renin-angiotensin-aldosterone system
Review
SARS-CoV2
Sartans
Zinc-chelating agents

Anmerkungen:

Date Completed 19.08.2021

Date Revised 07.11.2023

published: Electronic

Citation Status MEDLINE

doi:

10.3390/cells10071752

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM329041886